In: Herz Kardiovaskuläre Erkrankungen, 2007, vol. 32, no. 4, p. 296-300
|
In: Herz Kardiovaskuläre Erkrankungen, 2007, vol. 32, no. 4, p. 268-273
|
In: Herz, 2011, vol. 36, no. 3, p. 241-253
|
In: European Heart Journal, 2015, vol. 36, no. 32, p. 2167-2176
|
In: European Heart Journal, 2012, vol. 33, no. 10, p. 1214-1222
|
In: European Heart Journal, 2014, vol. 35, no. 29, p. 1932-1948
|
In: European Heart Journal, 2012, vol. 33, no. 11, p. 1334-1343
|
In: Trials, 2014, vol. 15, no. 1, p. 9
Background: Second-generation everolimus-eluting stents (EES) and third generation biolimus-eluting stents (BES) have been shown to be superior to first-generation paclitaxel-eluting stents (PES) and second-generation sirolimus-eluting stents (SES). However, neointimal proliferation and very late stent thrombosis is still an unresolved issue of drug-eluting stent (DES) implantation overall. The...
|
In: European Heart Journal, 2012, vol. 33, no. 11, p. 1334-1343
Aims Late acquired incomplete stent apposition (ISA) is more common after drug- eluting stent (DES) than bare metal stent (BMS) implantation and has been associated with vascular hypersensitivity and stent thrombosis (ST). We investigated the impact of incidentally discovered ISA as assessed by intravascular ultrasound (IVUS) 8 months after DES implantation on the long-term clinical...
|